Provided by Tiger Trade Technology Pte. Ltd.

Roivant Sciences Ltd.

35.72
+0.22000.62%
Post-market: 35.50-0.2200-0.62%19:30 EDT
Volume:4.37M
Turnover:155.72M
Market Cap:25.80B
PE:-76
High:36.00
Open:35.61
Low:35.19
Close:35.50
52wk High:42.50
52wk Low:15.25
Shares:722.41M
Float Shares:581.00M
Volume Ratio:0.76
T/O Rate:0.75%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4700
EPS(LYR):-0.5400
ROE:-8.52%
ROA:-16.48%
PB:6.10
PE(LYR):-66.15

Loading ...

Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16

THOMSON REUTERS
·
Sep 08

Roivant to Present Phase 2 PHocus Mosliciguat Topline Data in PH-ILD at ERS Congress Sept. 8, 2026

Reuters
·
Sep 06

Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented

Reuters
·
Sep 04

J.P. Morgan Reaffirms Their Buy Rating on Roivant Sciences (ROIV)

TIPRANKS
·
Sep 02

Roivant Sciences President, Immunovant CEO Eric Venker Disposes of Common Shares Worth $7.15 Million

Reuters
·
Sep 02

NASD Most Active Issues

Dow Jones
·
Sep 01

Immunovant Director Atul Pande Disposes of 1,500 Common Shares Worth $64,905

Reuters
·
Aug 29

Roivant Sets Price for New Rare Disease Drug Lisraya at $35,000 a Month

Reuters
·
Aug 28

Lisraya is Commercially Available NOW - Roivant Presentation

THOMSON REUTERS
·
Aug 28

Roivant Sciences Exec Says Lisraya Will be Available at List Price of $35,000 for a 30-Day Supply

THOMSON REUTERS
·
Aug 28

Roivant Sciences Price Target Maintained with a $41.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 28

Roivant Sciences Gets FDA Approval for LISRAYA in Dermatomyositis; Shares Rise

MT Newswires Live
·
Aug 28

Priovant Therapeutics - Lisraya NOW Available in the U.S.

THOMSON REUTERS
·
Aug 28

Priovant Announces FDA Approval of Lisraya™ (Brepocitinib) for Adults with Dermatomyositis; NOW Available in the U.S.

THOMSON REUTERS
·
Aug 28

US FDA Approves Roivant-Priovant's Skin Disease Drug

Reuters
·
Aug 28

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

Reuters
·
Aug 28

FDA: Lisraya is the First FDA-Approved Oral Treatment Option for Patients with Dermatomyositis

THOMSON REUTERS
·
Aug 28

Roivant Says JAMA Dermatology Publishes Phase 3 VALOR Data Showing Brepocitinib Improves Dermatomyositis Skin Outcomes

Reuters
·
Aug 26

Jama Dermatology Publishes Skin-Specific Outcomes from Phase 3 Valor Trial of Brepocitinib in Dermatomyositis

THOMSON REUTERS
·
Aug 26

Roivant President, CIO Mayukh Sukhatme Disposes of Common Shares Worth $12.47 Million

Reuters
·
Aug 22